Oncopharmpod
Pralsetinib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:11:47
- More information
Informações:
Synopsis
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
